Decibel Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DBTX Nasdaq 8731 https://www.decibeltx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Decibel Therapeutics Inc

Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors - Mar 21st, 2023 11:00 am
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update - Mar 14th, 2023 8:05 pm
private equity firms who own 39% along with institutions invested in Decibel Therapeutics, Inc. (NASDAQ:DBTX) saw increase in their holdings value last week - Mar 2nd, 2023 10:52 am
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference - Feb 16th, 2023 12:00 pm
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting - Feb 9th, 2023 12:00 pm
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $11 (or More) - Feb 8th, 2023 4:05 pm
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO - Jan 24th, 2023 12:00 pm
Will Decibel Therapeutics (NASDAQ:DBTX) Spend Its Cash Wisely? - Jan 20th, 2023 5:08 pm
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update - Nov 9th, 2022 9:45 pm
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO - Nov 2nd, 2022 11:00 am
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss - Oct 17th, 2022 11:00 am
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors - Oct 12th, 2022 11:00 am
Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit - Sep 22nd, 2022 11:00 am
Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO - Sep 20th, 2022 11:00 am
Decibel Therapeutics, Inc. (NASDAQ:DBTX) insider upped their holding by 63% earlier this year - Sep 9th, 2022 2:53 pm
Decibel Therapeutics to Participate in Upcoming Investor Conferences - Aug 31st, 2022 11:00 am
Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation - Aug 13th, 2022 2:34 pm
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update - Aug 10th, 2022 8:30 pm
Could The Decibel Therapeutics, Inc. (NASDAQ:DBTX) Ownership Structure Tell Us Something Useful? - Jul 1st, 2022 1:03 pm
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy - Jun 28th, 2022 11:00 am